What's breaking now, across thousands of outlets.
For nearly as long as they've been approved for diabetes and weight loss, GLP-1 drugs have captured the public imagination as a possible solution to diseases far beyond metabolic disorders. That potential is now inching ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
A new study identifies a stable, brain-derived RNA molecule in the bloodstream that accurately predicts whether a patient will respond to common SSRI antidepressants, potentially saving months of trial-and-error treatments.
The results of numerous high-impact Phase III clinical trials that could affect kidney-related medical care were presented in person at American Society of Nephrology Kidney Week 2026, Oct. 22–25.
He received his diagnosis on his birthday.
Runaway applied behavior analysis spending exposes the moral hazard at the heart of Medicaid’s financing architecture.
Plus more from Baxter and United Therapeutics. Sanofi starts construction of an insulin factory: Sanofi has broken ground on a new 36,000-square-meter manufacturing facility at its site in Frankfurt, which ...
